EyePoint Pharmaceuticals, Inc., a company developing and commercializing therapeutics for serious eye disorders, has entered into a lease agreement to design and construct a 40,000-sq.-ft. manufacturing facility in Northbridge, MA to support the global manufacturing of programs, including EYP-1901 and YUTIQ.
The standalone manufacturing facility will be GMP compliant to meet U.S. FDA and European Medicines Agency (EMA) standards and support EYP-1901’s clinical supply and commercial readiness upon regulatory approval. The building will also have the capacity and capabilities to support EyePoint’s commercial business and expanding pipeline. The new facility is expected to be operational in the second half of 2024.
“As EyePoint continues to advance our retinal disease-focused pipeline and commercial business, the ability to efficiently and reliably manufacture our products is key to our mission of bringing innovative treatment options to patients living with serious eye disorders,” said Nancy Lurker, Chief Executive Officer of EyePoint Pharmaceuticals. “This new facility provides us with significant manufacturing capacity to accelerate the clinical development and future commercial production for EYP-1901, as well as support global demand for our U.S. FDA and China NMPA approved therapy, YUTIQ. This strategic investment in a commercial scale facility reflects our commitment to EYP-1901, YUTIQ and the focus on building a strong pipeline for long-term shareholder value.”
